A 56-year-old woman with rheumatoid arthritis treated with methotrexate (MTX) was admitted to our hospital due to multiple liver tumors. Contrast-enhanced computed tomography (CT) revealed multiple hypovascular masses, and 18F-fluorodeoxyglucose positron emission tomography CT showed diffuse abnormal accumulation in the liver only. We therefore made a diagnosis of MTX-related primary hepatic lymphoma (MTX-PHL) exhibiting features of diffuse large B-cell lymphoma. Although MTX has been reported to increase the risk of lymphoproliferative disorders, MTX-PHL has not been reported previously. The present case is the first case in which MTX appears to have been involved in the development of PHL.
Introduction
Methotrexate (MTX) is one of the most frequently used immunosuppressive agents for treating autoimmune diseases, such as rheumatoid arthritis (RA). MTX was first introduced as a chemotherapeutic agent for use in various malignancies, including acute lymphoblastic leukemia, and inhibits folatedependent steps in the synthesis phase of DNA replication (1) . In accordance with cumulative evidence for its effectiveness for RA, MTX is widely used as a diseasemodifying antirheumatic drug (DMARD), both as induction and maintenance therapy. Several studies have suggested a relationship between lymphoproliferative disorders (LPD) and MTX in RA patients, a condition referred to as MTXrelated LPD (MTX-LPD) (2) (3) (4) . Because the number of RA patients treated with immunosuppressive agents is increasing, cases of MTX-LPD may also increase in the future (5) . However, the liver is rarely involved in this disorder (6) , and there are no reports of MTX-related primary hepatic lymphoma (MTX-PHL). We herein present the first case of PHL that developed during treatment with MTX for RA.
Case Report
A 56-year-old woman visited a local hospital with complaints of malaise, weight loss and fever lasting for two months. She had been diagnosed with RA seven years previously due to pain in the joints in both hands and wrists associated with prominent morning stiffness and elevation of the rheumatoid factor (RF) titer and erythrocyte sedimentation rate (ESR). Although MTX was initially administered at a dose of 6 mg/week, the patient's symptoms did not resolve. Subsequently, the dose of MTX was slowly titrated from 6 to 16 mg/week over one year. For the past six years, the patient's symptoms of RA had been controlled with MTX at a dose of 16 mg/week, and she had no history of sicca symptoms to date. However, abdominal ultrasonography (US) performed at the local hospital demonstrated multiple tumors throughout the liver, and the patient was therefore introduced to our hospital for a further evaluation. The physical findings showed hepatomegaly without lymph node enlargement. The laboratory data were as follows: aspartate 
IU/L and uric acid= 12.0 mg/dL. The concentration of serum soluble interleukin-2 receptor (sIL-2R) was elevated at 4,044 U/mL (normal range: 254-534 U/mL). In addition, the anti-nuclear antibody (ANA) and RF titers were increased at 160-fold and 22.3 IU/mL (normal range: <15 IU/mL), respectively. Other laboratory findings were either "negative" or "within the normal range," including anti-Ro/SS-A antibodies, anti-Ro/SS-B antibodies, viral markers of hepatitis B virus (HBV) and hepatitis C virus (HCV) and tumor markers, such as α-fetoprotein (AFP), protein induced by vitamin K absence or antagonist (PIVKA)-II, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9. The laboratory data on admission are summarized in Table. US revealed multiple low-echoic nodules in the swollen liver, although no swelling of the spleen was noted. Contrast-enhanced computed tomography (CT) of the liver demonstrated multiple hypovascular homogenous masses in the bilateral hepatic lobes in the arterial, portal and equilibrium phases (Fig. 1) . The intrahepatic portal vein, although patent, was involved and narrowed by the tumors. 18F-fluorodeoxyglucose positron emission tomography CT (FDG-PET/CT) disclosed marked hepatomegaly with diffuse abnormal accumulation [maximum standardized uptake value, standardized uptake value max (SUVmax) =19.80]; however, no other sites of abnormal accumulation were found, including the spleen, lymph nodes and bone marrow (Fig. 2) . In order to make a pathological diagnosis, we performed a US-guided percutaneous aspiration biopsy of the hepatic nodules using a 21-G needle. Hematoxylin and eosin staining showed diffuse infiltration of large atypical lymphoid cells (Fig. 3a, b) , and immunostaining of the tumor cells showed these cells to be positive for CD10, CD79a and CD20, but negative for CD5 (Fig. 3c-f) . Epstein-Barr virus (EBV)-encoded RNA in situ hybridization (EBER-ISH) was also negative. Therefore, a histological diagnosis of diffuse large B-cell lymphoma (DLBCL) was made. Based on these findings and the administration of MTX for RA, we diagnosed the patient with "other iatrogenic immunodeficiency-associated lymphoproliferative disorders" according to the World Health Organization (WHO) classification (7) . As a bone marrow biopsy showed no lymphoma cells and PET demonstrated no other abnormal regions, we ultimately diagnosed the patient with MTX-PHL, clinical stage IVB, high-intermediate risk, according to the international prognostic index (IPI). Following the definitive diagnosis, the patient immediately stopped receiving MTX. Three weeks after the withdrawal of MTX, no improvements were observed in the serum LDH level or liver tumors on US. Hence, we administered rituximab, cyclophosphamide, adriamycin, vincristine and prednisolone (R-CHOP) therapy, which is the standard treatment for malignant lymphoma. Consequently, the patient's symptoms and laboratory and imaging findings immediately improved, and she achieved complete remission after receiving six courses of treatment. Six months after the completion of R-CHOP therapy, no further treatment for MTX-PHL was required (Fig. 4) .
Discussion
Immunocompromised patients have a higher risk of LPD than healthy individuals (8) . Recently, a number of reports have shown that patients with RA treated with immunosuppressive agents, including MTX, have a high prevalence of LPD (2) (3) (4) . Approximately 40-50% of MTX-LPD cases occur in extranodal sites, including the gastrointestinal tract, skin, lungs, kidneys and soft tissue (6) . However, cases of MTX-PHL, such as the present case, have not been previously reported.
Although malignant lymphoma often involves the liver, PHL accounts for less than 1% of cases of extranodal lymphoma (9), perhaps because there are few lymphoid tissues in the liver, except in the portal area (10) . As imaging examinations of PHL may reveal various findings, including solitary, multiple or infiltrative patterns, it is difficult to obtain a correct diagnosis based on imaging alone (11) . Hence, histological examinations are indispensable for making a definitive diagnosis of PHL (12). Ohsawa et al. proposed the following definition of PHL: (a) no evidence of visceral or distant nodal involvement on the first admission, (b) the absence of splenomegaly and (c) the absence of a leukemic blood picture together without evidence of myelosuppression (13) . Our patient satisfied all of these criteria.
The etiology of PHL remains unknown, although viruses, such as HBV, HCV, EBV and human immunodeficiency virus, have been implicated (14) . In the present case, serologic tests for HBV, HCV and EBER-ISH were negative, and the patient had been receiving MTX for the treatment of RA prior to the onset of PHL. Therefore, we suspected that the MTX therapy may have been related to the development of PHL. Since Ellman et al. reported a case of LPD occurring under medication with MTX for RA (15) , the relationship between LPD and MTX has been widely discussed (2) (3) (4) 16) . LPD occasionally develops in individuals with immune deficiencies (1), and MTX is an immunosuppressive agent used to treat autoimmune diseases, including RA. According to the recent WHO classification for lymphoid neoplasms, MTX-LPD is defined and categorized as "other iatrogenic immunodeficiency-associated lymphoproliferative disorders" (7) . Therefore, we considered the present case to involve MTX-PHL. In addition, the relative risk of developing LPD in patients with RA is 2.0 to 5.5 times higher than that observed in the general population (17) (18) (19) . These findings suggest that LPD may develop under the immunosuppressive state induced by MTX as well as the hyperimmune state associated with RA itself. In one study, the median duration of RA and MTX treatment was reported to be 96 and 56 months, respectively, with a median cumulative dose of 864 mg, among 29 RA patients with MTX-LPD (20) . In the present case, the duration of MTX treatment was 80 months and the total dose of MTX was over 4,000 mg. This suggests that the immunosuppressive state induced by MTX may have played a major role in the development of PHL in the current patient.
Previous reports have indicated that EBV may be related to the development of MTX-LPD (21, 22) . For example, (23), and cell cycle dysregulation and latent EBV infection have been reported to be important factors for the development of LPD in autoimmune disease patients with an immunosuppressed condition due to treatment with MTX (24) . On the other hand, the rate of positivity for EBV is higher in LPD patients with RA than in LPD patients without RA, although there are no differences in the status of EBV between MTX-LPD and non-MTX-LPD patients with RA (25) . Therefore, the relationship between EBV and the development of MTX-LPD is controversial. There is one report that EBV may be associated with spontaneous regression following the withdrawal of MTX in MTX-LPD patients, and Salloum et al. reported that EBV was detected in eight of 10 patients who responded to the withdrawal of MTX, whereas only one of six EBV-negative patients responded to MTX withdrawal (26) . The present patient also did not respond to the withdrawal of MTX and subsequently required R-CHOP therapy. Hence, the presence of EBV may be a predictive factor for the efficacy of MTX withdrawal.
There is no established standard treatment for MTX-LPD due to the lack of randomized controlled studies. However, approximately 55% of MTX-LPD patients have been reported to improve following the withdrawal of MTX, without additional antitumor therapy (26) . Therefore, MTX withdrawal should be considered as the first treatment option, regardless of the status of EBV. Even if this strategy does not lead to an accurate diagnosis, immediate MTX withdrawal may be necessary, as a case of MTX-LPD associated with a bulky mass that developed under the short-term administration of MTX has been reported (27) . In any case, when the withdrawal of MTX is selected as a treatment option for MTX-LPD, close monitoring is required due to the potential for rapid tumor growth within a short period of time, as observed in the current case.
Hepatotoxicity is a major adverse effect associated with MTX. The frequency of elevated liver enzymes has been reported to be 7.5 to 26.0% among patients treated with MTX (28, 29) , and ALT is a representative marker of MTXrelated hepatotoxicity (30, 31) . On the other hand, the AST, LDH and ALP levels are elevated in many PHL patients (32) . The present patient also demonstrated elevation of AST, LDH and ALP.
In conclusion, it is important to check other liver enzymes and perform imaging examinations in order to diagnose or exclude MTX-PHL in cases of elevated aminotransferase levels in RA patients treated with MTX.
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